Sinew Pharma has six major products in two applications on hepatotoxicity-free acetaminophen (AAP) and fatty liver disease. Our breakthrough product, the SNP-810, is significantly more safe with the same efficacy as the current Acetaminophen (AAP) market products. Our solution is paramount as AAP toxicity in all of the current market products is the most common cause of severe drug-induced liver injury. The third-party Charles River Laboratory also conducted a study, confirming that SNP-810 can protect the AAP-induced hepatotoxicity. Sinew Pharma, from Taiwan, has been granted 71 patents and applied for additional 33 patents. We are in Phase II/A trials for our NASH-curing drag which has a 3-in-1 impact. It prevents liver triglyceride & cholesterol accumulation; it is anti-inflammatory, and anti-fibrosis.